News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
US & Canada
C2C Services & Suppliers™
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
AesRx Appoints Jordan, CMO of Sickle Cell Disease Association of America, to Clinical Advisory Board
2/25/2010 11:33:24 AM
NEWTON, MA, February 25, 2010 — AesRx, LLC, announced today it has appointed Lanetta Jordan, MD, the Chief Medical Officer of the Sickle Cell Disease Association of America (SCDAA), to its Clinical Advisory Board. Dr. Jordan is also Director of the Department of Sickle Cell Services at Memorial Healthcare System in Hollywood, Florida, a position she has held since founding that department in 2004.
“We are delighted to add Dr. Jordan to our Clinical Advisory Board,” said Stephen R. Seiler, AesRx’s Chief Executive Officer. “She has demonstrated an extraordinary commitment to the treatment of sickle cell patients both in her work on behalf of the SCDAA and in her position as head of Memorial Healthcare System’s Department of Sickle Cell Services. Dr. Jordan’s passion and drive will be of great assistance to AesRx as we move Aes-103 into the clinic and push forward with this important development program for a unique sickle cell therapeutic.”
“I’m pleased to be able to join AesRx in this effort,” added Dr. Jordan. “There has been too little progress in finding new therapies for sickle cell patients. If successful, Aes-103 could create a new paradigm in the treatment of this devastating disease.”
Dr. Jordan was appointed the Chief Medical Officer of the Sickle Cell Disease Association of America in September 2008. As Director of the Department of Sickle Cell Services at Memorial Healthcare System, she heads activities which focus on adolescent and adult acute pain care, comprehensive follow-up care, research and grants, community outreach education, genetic counseling and screening, and an adolescent transition program. In 2004, Dr. Jordan spearheaded the successful Joint Commission Disease Specific Certification of Distinction for Sickle Cell Disease at Memorial Regional Hospital. She serves as Chair of the US Sickle Cell Disease Surveillance Workgroup and the Sickle Cell Disease United Voice Group both of which were created out the America Society of Pediatric Hematology, Oncology’s Sickle Cell Summit. Dr. Jordan was appointed to the state of Florida’s Health Care Transition Task Force for Youth and Young Adults with Disabilities. She is also a teacher and co-author of various articles, abstracts and policy briefs.
AesRx is a biopharmaceutical company dedicated to the development of products for two orphan diseases. The Company’s lead program (Aes-103) is targeted to the treatment of sickle cell disease. Sickle cell disease is a recessive disorder of the hemoglobin which can lead to a wide range of serious, sometimes life-threatening, conditions including: chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome, and cumulative damage to tissues and organs. More than 13 million individuals world-wide are afflicted with sickle cell disease. Aes-103 works by increasing the affinity of sickle hemoglobin for oxygen. Because only red blood cells with no bound oxygen will sickle, increasing the ability of the sickle red blood cells to bind oxygen reduces the number of cells that can sickle. AesRx is completing the pre-clinical development program for Aes-103 and expects to begin human clinical trials in 2010. AesRx’s second development program, Aes-210, is targeted to treat certain inflammatory diseases of the lower intestine, including distal ulcerative colitis, pouchitis and radiation induced proctitis. For more information, go to http://www.aesrx.com.
This press release contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio, pipeline and clinical programs (collectively the “Products”) of AesRx LLC (the “Company”), the market opportunities for the Products, the potential effectiveness of the Products based on the interpretation of past and/or planned pre-clinical data and the Company’s goals and objectives. These statements are subject to numerous risks and uncertainties.